CoChat

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden

Open access
Hedayati, Elham, Fracheboud, Lionel, Srikant, Vaidyanathan, Greber, David, Wallberg, Susanne, Linder Stragliotto, Christina · 2019 · PLOS ONE

Abstract

INTRODUCTION: Adjuvant trastuzumab is a standard of care in the treatment of Human Epidermal growth factor Receptor 2 (HER2) positive early breast cancer (eBC). Initially trastuzumab could only be administered intravenously (IV), however since 2013, a subcutaneous (SC) formulation with comparable efficacy and safety profile is available and preferred by patients. Trastuzumab SC does not require pharmacy preparation and has shorter administration time. The objective of this study was to estimate the economic efficiency of the SC formulation of trastuzumab by assessing the economic benefits of actual SC-driven process changes at one single Swedish healthcare institution. METHODS: This study analyzes changes in trastuzumab administration practice after the SC formulation was introduced at the Karolinska University Hospital. Process changes were identified and introduced in order to capitalize on the inherent work efficiency benefits of the SC formulation. Actual hospital data for 2015 were used to quantitatively estimate the annual economic impact of the changes. It encompassed administrative (i.e. non-medical) data of 178 newly diagnosed HER2-positive eBC patients and a total of 2,769 SC administrations. Realized economic benefits were expressed in hours saved by nurses, direct monetary cost savings and potential infusion fee revenue that could be earned through infrastructural revenue gains. RESULTS: In 2015, the replacement of IV infusion to SC administration generated total time savings of more than 1,100 hours, and led to direct monetary cost savings of 603,000 EUR. It unlocked a capacity gain of 1-2 additional administrations daily within the existing facility infrastructure. Given the current remuneration structure per administration, this revenue gain translated into an incremental revenue potential of up to 3 million EUR. CONCLUSION: Data from this study showed that the shift from trastuzumab IV to SC formulation resulted in significant economic effects in terms of departmental resources related to time, direct monetary cost savings, and infrastructural revenue gains.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0211783

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Summary of overall economic benefits encompassing cost savings as well as potential revenue gains through released capacity (thousands Euros; 2015).
Fig 1 Summary of overall economic benefits encompassing cost savings as well as potential revenue gains through released capacity (thousands Euros; 2015).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 39

Metadata

Authors
Hedayati, E., Fracheboud, L., Srikant, V., Greber, D., Wallberg, S., & Linder Stragliotto, C.
Affiliations
  • Karolinska University Hospital (SE)
  • Boston Consulting Group (United States) (US)
Corresponding author
Hedayati, Elham
Venue
PLOS ONE
Published
2019-02-04
Volume
14
Issue
2
Pages
e0211783
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2913996563
Cited by
39
References
13
Citations by year
2026: 3 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 1
FWCI
4.68
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
F. Hoffmann-La Roche (0000)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
subcutaneous trastuzumab, HER2-positive early breast cancer, adjuvant therapy, economic efficiency, cost reduction, hospital resource utilization, intravenous to subcutaneous switch
MeSH terms
Trastuzumab, Adult, Breast Neoplasms, Costs and Cost Analysis, Female, Hospitals, University, Humans, Injections, Subcutaneous, Middle Aged, Sweden, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden. https://app.cochat.ai/papers/10.1371/journal.pone.0211783
The paper
Hedayati, E., Fracheboud, L., Srikant, V., Greber, D., Wallberg, S., & Linder Stragliotto, C. (2019). Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden. PLOS ONE. https://doi.org/10.1371/journal.pone.0211783

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.